Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -0.29
- Piotroski Score 2.00
- Grade Hold
- Symbol (NVRO)
- Company Nevro Corp.
- Price $4.36
- Changes Percentage (3.07%)
- Change $0.13
- Day Low $4.21
- Day High $4.47
- Year High $22.64
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/19/2025
- Fiscal Year End N/A
- Average Stock Price Target $7.00
- High Stock Price Target $125.00
- Low Stock Price Target $5.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.28
- Trailing P/E Ratio -4.07
- Forward P/E Ratio -4.07
- P/E Growth -4.07
- Net Income $-92,213,000
Income Statement
Quarterly
Annual
Latest News of NVRO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Nevro Corp. (NVRO) Stock Price, News, Quote & History
Morgan Stanley's report values the BCI market at $400 billion, indicating its potential as a significant investment in medtech. Nevro Corp introduces Nevro1™ SI Joint Fusion System, showing advantag...
By Yahoo! Finance | 3 days ago -
Engaged Capital Calls Nevro Corp. (NVRO) to Focus on Improving Profitability and Stop Pursuing Acquisitions
Activist investors are increasingly pressuring companies for strategic changes to unlock value. Nevro Corp. (NYSE:NVRO) faces activist pressure, with Engaged Capital advocating for profitability impro...
By Yahoo! Finance | 3 months ago
